GT Biopharma Provides Second Quarter 2021 Business Update
Announced Positive Interim Data Results Demonstrating Substantial Reduction in AML/MDS Cancer Cells and Bone Marrow Blast Levels from GTB-3550 TriKE® Phase I Clinical Trial Entered Research Agreement with Dr. Jeffrey